



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 17 January 1995

1/17/95
Date

And Richard
Signature

8
1/27/95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

SPTILER et al.

Serial No.: 08/105,444

Group Art Unit: 1806

Filing Date: 11 August 1993

Examiner: Unknown

Title: PROSTATIC CANCER
VACCINE

RECEIVED
JAN 20 1995
GROUP 1806

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR 1.97

The Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

In addition to the Information Disclosure Statement Under 37 CFR 1.97 mailed to the PTO on 1 November 1994, the citations cited in the International Search Report, copies attached, may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure as defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in the application.

This Supplemental Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under U.S.C. § 102.

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

MORRISON & FOERSTER
2000 Pennsylvania Avenue, N.W.
Suite 5500
Washington, D.C. 20006-1888
Tel: (202) 887-1500
Fax: (202) 887-0763